Skip to content
ClinCalc Pro
Menu
Phosphate Binder (Non-Calcium-Based)

Lanthanum Carbonate

Brand names: Fosrenol

Lanthanum carbonate is a calcium-free, aluminium-free phosphate binder used to control hyperphosphataemia in chronic kidney disease, particularly in dialysis patients.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

In the gastrointestinal tract lanthanum binds dietary phosphate to form insoluble, poorly absorbed lanthanum phosphate, reducing phosphate absorption.

Prescribing in practice

  • Tablets must be chewed thoroughly and taken with or immediately after food to bind phosphate effectively and reduce the risk of gastrointestinal obstruction.
  • Gastrointestinal effects, and rarely bowel obstruction, perforation or ileus, can occur, so use caution in patients with gut motility disorders.
  • Separate administration from other oral medicines whose absorption may be impaired by binders.

Monitoring

Monitor serum phosphate, and calcium, to guide dose titration to target while avoiding over-suppression.

Counselling the patient

  • Always chew the tablets fully and take them with food, never on an empty stomach.
  • Report persistent constipation, severe abdominal pain or vomiting.
  • Take other tablets at a different time from your phosphate binder as advised.

Evidence & guidelines

Renal mineral and bone guidance supports phosphate binders such as lanthanum carbonate for managing hyperphosphataemia in CKD.

Reference: KDIGO CKD-MBD Clinical Practice Guideline Update 2017; Hutchison et al. NDT 2005 (lanthanum phase III); MHRA SPC Fosrenol; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.